Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Viridian Therapeutics, Inc. (VRDN : NSDQ)
 
 • Company Description   
Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

Number of Employees: 252

 
 • Price / Volume Information   
Yesterday's Closing Price: $17.24 Daily Weekly Monthly
20 Day Moving Average: 3,575,537 shares
Shares Outstanding: 103.07 (millions)
Market Capitalization: $1,777.01 (millions)
Beta: 0.82
52 Week High: $34.29
52 Week Low: $13.18
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 21.15% 15.23%
12 Week -41.54% -45.96%
Year To Date -44.60% -47.74%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
221 CRESCENT STREET SUITE 103A
-
WALTHAM,MA 02453
USA		 ph: 617-272-4600
fax: 760-537-4101		 ir@viridiantherapeutics.com http://www.viridiantherapeutics.com
 
 • General Corporate Information   
Officers
Stephen Mahoney - President; Chief Executive Officer and Director
Tomas Kiselak - Chairman
Seth Harmon - Chief Financial Officer
Sarah Gheuens - Director
Jeff Ajer - Director

Peer Information
Viridian Therapeutics, Inc. (CORR.)
Viridian Therapeutics, Inc. (RSPI)
Viridian Therapeutics, Inc. (CGXP)
Viridian Therapeutics, Inc. (BGEN)
Viridian Therapeutics, Inc. (GTBP)
Viridian Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92790C104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/05/26
Share - Related Items
Shares Outstanding: 103.07
Most Recent Split Date: 11.00 (0.07:1)
Beta: 0.82
Market Capitalization: $1,777.01 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.00 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.71 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.53
Price/Cash Flow: -
Price / Sales: 25.06
EPS Growth
vs. Year Ago Period: -3.45%
vs. Previous Quarter: 16.67%
Sales Growth
vs. Year Ago Period: 95.83%
vs. Previous Quarter: 6.82%
ROE
03/31/26 - -80.19
12/31/25 - -83.25
09/30/25 - -78.50
ROA
03/31/26 - -48.84
12/31/25 - -50.38
09/30/25 - -47.13
Current Ratio
03/31/26 - 15.15
12/31/25 - 12.65
09/30/25 - 11.28
Quick Ratio
03/31/26 - 15.15
12/31/25 - 12.65
09/30/25 - 11.28
Operating Margin
03/31/26 - -490.31
12/31/25 - -483.57
09/30/25 - -426.58
Net Margin
03/31/26 - -490.31
12/31/25 - -483.57
09/30/25 - -426.58
Pre-Tax Margin
03/31/26 - -508.46
12/31/25 - -483.57
09/30/25 - -426.58
Book Value
03/31/26 - 4.89
12/31/25 - 6.18
09/30/25 - 3.85
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.10
12/31/25 - 0.08
09/30/25 - 0.07
Debt-to-Capital
03/31/26 - 7.35
12/31/25 - 6.47
09/30/25 - 3.99
 

Powered by Zacks Investment Research ©